Feeds:
Posts
Comments

Archive for the ‘Biopsy’ Category

NEW PROSTATE CANCER INFOLINK:  A new way to test negative biopsy samples to see if in fact prostate cancer is present will be tested on 500 US volunteers. READ MORE>

Gen-Probe announced yesterday that it has begun a clinical trial designed to seek U.S. regulatory approval of the PROGENSA® PCA3 assay. Gen-Probe to market their PCA3 test only for the evaluation of prostate cancer risk in patients who had had at least one negative biopsy.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Interpretation of biopsy sample slides by pathologists has played a significant role in a Gleason score “shift” over the past 15 years, according to a new study. However, there are some questions over some of the researchers’ conclusions. READ MORE>

Read Full Post »

URO TODAY: Researchers have developed an accurate tool to determine the chances of finding prostate cancer in men who have already had a negative biopsy and for whom a repeat biopsy is being considered. READ MORE>

Read Full Post »

URO TODAY: The UK National Institute for Health and Clinical Excellence guidance recommends conservative management of men with ‘low-risk’ localised prostate cancer, monitoring the disease using changes to PSA over time and re-biopsy. However, there is little evidence of the changes in PSA level that should alert to the need for clinical re-assessment. READ MORE> and HERE> (New Prostate Cancer Infolink)

Read Full Post »

URO TODAY: Fragmentation of a prostate biopsy core can potentially distort analysis of the cancer’s extent and aggressiveness, a new study has confirmed. READ MORE>

Read Full Post »

URO TODAY: Biopsies are not particularly useful in determining how laterally widespread or close to the margins tumours are in prostate cancer patients. READ MORE> And HERE>

Read Full Post »

URO TODAY: The end-fire transrectal ultrasound probe improves biopsy detection rate of prostate cancer compared to the side-fire probe. READ MORE>

Read Full Post »

JULY 31: URO TODAY: What’s the most accurate way your specialist can predict your fate when you first learn you have prostate cancer? Using something called a nomogram, according to latest analysis. READ MORE>

Researchers at the University of Montreal Health Center reviewed tools available to clinicians involved in treatment decisions in newly diagnosed prostate cancer and examined their accuracy to provide individual life expectancy.

“…nomograms provide the most accurate health-adjusted life expectancy prognostication,” they conclude.

What’s a nomogram?

It’s a calculation that gives an estimate – in this case, of life expectancy – after known information is fed into it.

The Memorial Sloan Kettering Cancer Center in the US has one for prostate cancer on its website. Anyone who knows the results of PSA, biopsy and Gleason grade can use it: CLICK HERE>

Here’s an example:

Nomogram

Read Full Post »

JULY 18: URO TODAY: A new gene test called the “4-gene RT-PCR test” can be used to detect Gleason grade 3 and grade 4 cancer cells in prostate tissue and may be useful as an adjunct to the pathology examination of prostate tissue taken at biopsy or prostatectomy. READ MORE>

Read Full Post »

JULY 4: URO TODAY: Fifteen or more biopsy cores are best for patients with a prostate volume greater than 53cc and PSA higher than 18, according to researchers in Israel. Three consecutive biopsies using that approach should be enough to give doctors confidence cancer is not present. READ MORE>

Read Full Post »

« Newer Posts - Older Posts »